If approved, Pfizer’s sasanlimab will distinguish itself from Merck’s blockbuster Keytruda as the first PD-1 inhibitor ...

Pfizer’s “golden egg” has hatched. The subcutaneous PD-1 inhibitor improved outcomes when added to the standard of care in ...

It’s the first major partnership for Janux, which was set up in 2017, and could be the last to be organised by Merck’s R&D head Roger Perlmutter who is retiring from the big pharma company at ...

The year 2024 saw the U.S. stock market make new records, with major indices breaching key milestones. While many stocks witnessed a stellar rally this year, analysts still expect some blue-chip ...

Merck & Co is pressing home its precious advantage in first line non-small cell lung cancer, with new data from a Keytruda + chemo combination suggesting patients' lives could be significantly ...

The Dutch startup ecosystem continues to captivate international attention. The State of Dutch Tech 2024 report reveals that in 2023, acquisitions in the Dutch startup ecosystem saw a notable increase ...

but being beaten by compatriot Roger De Vlaeminck in the final at Lombardia was a bitter pill to swallow. While Merckx would go on to win four more Monuments in his career, the man widely ...

The media will focus on a handful of pop acts when the true action will be in smaller acts outside the national consciousness ...

With Rik Van Looy, who passed away just days before his 91st birthday, gone is a true icon of world and Belgian cycling in particular, as other legends of the sport, Eddy Merckx and Roger De Vlaeminck ...

Merck & Co. has added a second GLP-1 candidate to its pipeline, paying China’s Hansoh Pharma $112 million upfront for a preclinical drug. The Big Pharma already has efinopegdutide, a dual GLP-1 ...

Empire Market will hold its sixth annual chili cook-off Saturday, Jan. 18. Cash prizes, trophies and bragging rights are on the line. Judging for the event will start at 10 a.m., and tasting is open ...

Merck (NYSE:MRK) and Chinese biopharmaceutical company Hansoh Pharma (OTCPK:HNSPF) announced a global licensing deal on Wednesday to develop HS-10535, an oral GLP-1 receptor agonist targeted at ...